Wall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to “Hold”

MiNK Therapeutics (NASDAQ:INKT) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

INKT has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Wednesday, October 8th. Zacks Research raised MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $35.00.

MiNK Therapeutics Stock Up 1.1%

Shares of NASDAQ:INKT opened at $11.96 on Monday. The firm has a market cap of $56.09 million, a price-to-earnings ratio of -3.95 and a beta of 0.34. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00. The company’s fifty day simple moving average is $11.87 and its 200 day simple moving average is $14.26.

MiNK Therapeutics (NASDAQ:INKT) last announced its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.21. Research analysts expect that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.